Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

NonInterventional, Multicenter, Prospective, European Study to Describe the Effectiveness of Trabectedin + PLD in the Treatment of Relapsed Ovarian Cancer (ROC) Patients According to SmPC Regardless of Previous Use of an Antiangiogenic Drug

Next Previous
X
Search
Trial Profile

NonInterventional, Multicenter, Prospective, European Study to Describe the Effectiveness of Trabectedin + PLD in the Treatment of Relapsed Ovarian Cancer (ROC) Patients According to SmPC Regardless of Previous Use of an Antiangiogenic Drug

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 02 Nov 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Trabectedin (Primary) ; Doxorubicin liposomal
  • Indications Carcinoma; Ovarian cancer; Peritoneal cancer
  • Focus Therapeutic Use
  • Acronyms NIMES-ROC
  • Sponsors PharmaMar

    • Most Recent Events

    • 30 Jun 2020 Status changed from active, no longer recruiting to completed.
    • 04 Nov 2019 According to a PharmaMar Media Release, data from this trial were presented at the European Congress of Oncological Gynecology (ESGO), being held from 2-5 November in Athens, Greece.
    • 04 Nov 2019 Results presented in a PharmaMar Media Release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top